Research output: Contribution to journal › Article › peer-review
T Vaikunthanathan, Niloufar Safinia, Dominic Boardman, Robert Lechler, Giovanna Lombardi
Original language | English |
---|---|
Pages (from-to) | 197-210 |
Journal | Clinical and Experimental Immunology |
Volume | 189 |
Issue number | 2 |
Early online date | 25 May 2017 |
DOIs | |
Accepted/In press | 31 Mar 2017 |
E-pub ahead of print | 25 May 2017 |
Published | Aug 2017 |
The concept of regulatory T cell (Treg ) therapy in transplantation is now a reality. Significant advances in science and technology have enabled us to isolate human Tregs , expand them to clinically relevant numbers and infuse them into human transplant recipients. With several Phase I/II trials under way investigating Treg safety and efficacy it is now more crucial than ever to understand their complex biology. However, our journey is by no means complete; results from these trials will undoubtedly provoke both further knowledge and enquiry which, alongside evolving science, will continue to drive the optimization of Treg therapy in the pursuit of transplantation tolerance. In this review we will summarize current knowledge of Treg biology, explore novel technologies in the setting of Treg immunotherapy and address key prerequisites surrounding the clinical application of Tregs in transplantation.
King's College London - Homepage
© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454